Table 2. IC50's of the fluoropyrimidines (expressed in μM) in the presence or absence of TPI, for the different cell lines.
| Cell line | 5FU | 5FU +TPI | DMF | 5′DFUR | 5′DFUR +TPI | DMF | TFT | TFT +TPI | DMF | FT | FT+TPI | DMF |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HT29 | 5.4±1.3 | 6.6±0.2 | 1.2 | 176.9±27.3 | 275.8±15.9 | 1.6 | 3.9±1.0 | 3.7±0.7 | 0.9 | 201.1±37.9 | 283.2±81.3 | 1.4 |
| Lovo | 1.1±0.1 | 2.5±0.2 | 2.2b | 24.9±5.1 | 103.5±17.3 | 4.2a | 0.5±0.1 | 0.4 ±.0.1 | 1.0 | 97.2±15.5 | 86±24.8 | 0.9 |
| WiDR | 2.5±0.5 | 4.7±1.0 | 1.9b | 90.1±12.0 | 222.5±25.0 | 2.5b | 2.5±0.8 | 3.5±1.0 | 1.4 | 203.9±44.9 | 236.1±27.8 | 1.2 |
| Colo320 | 2.3±0.2 | 2.5±0.2 | 1.1 | 61.7±5.8 | 65.0±1.1 | 1.1 | 0.4±0.1 | 0.4±0.1 | 0.9 | 119.4±7.2 | 141.7±11.2 | 1.2 |
| Colo320TP1 | 0.2±0.1 | 2.8±0.3 | 14.7c | 0.06±0.02 | 81.0±10.5 | 1396.6b | 0.5±0.04 | 0.6±0.1 | 1.1 | ND | ND | — |
| SW948 | 3.1±1.0 | 4.0±1.7 | 1.3 | 208.9±7.6 | 255.6±14.3 | 1.2 | ND | ND | — | ND | ND | — |
| SW1398 | 2.0±0.6 | 3.2±0.6 | 1.6 | 134.8±32.9 | 202.0±37.4 | 1.5 | ND | ND | — | 275±39.7 | 191.4±22.1 | 0.7 |
| H460 | 2.0±0.2 | 8.6±0.4 | 4.3c | 10.9±1.7 | 332.9±13.4 | 30.5c | 0.6±0.1 | 0.6±0.03 | 0.9 | ND | ND | — |
| H460TP2 | 1.6±0.2 | 11.1±1.0 | 6.8c | 4.2±0.5 | 275.0±16.1 | 65.1c | 0.7±0.04 | 0.5±0.03 | 0.8 | ND | ND | — |
Significant differences between drug and drug with TPI (Student t-test):
a
P<0.05
b
P<0.01
c
P<0.001
Thymidine phosphorylase inhibitor was present in a final concentration of 10 μM, 24 h before drugs were added. DMF is the dose-modifying factor calculated as (IC50+TPI)/IC50.
ND=not done.